Publisher： Bentham Science Publishers
E-ISSN： 1875-5607|3|1|51-60
ISSN： 1389-5575
Source： Mini Reviews in Medicinal Chemistry, Vol.3, Iss.1, 2003-02, pp. : 51-60
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
The ability of peptide nucleic acids and hammerhead ribozymes, which target different subunits of human telomerase, to efficiently inhibit the enzyme's catalytic activity has been clearly demonstrated in several in vitro studies carried out in human immortalized and cancer cell lines. However, the actual efficacy of these molecules still needs to be validated in in vivo human tumor models, and such validation appears to be largely dependent on the development of reliable systems for their intracellular delivery.
Related content
Telomerase Inhibition in Cancer Therapeutics: Molecular-Based Approaches
Current Medicinal Chemistry, Vol. 13, Iss. 24, 2006-10 ,pp. :
Access to resources
Recommend
Hammerhead ribozymes for target validation
Expert Opinion on Therapeutic Targets, Vol. 6, Iss. 2, 2002-04 ,pp. :
Nucleobase Modifications in Peptide Nucleic Acids
Current Topics in Medicinal Chemistry, Vol. 7, Iss. 7, 2007-04 ,pp. :